Shares of TransMedics Group TMDX were flat in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 30.95% over the past year to ($0.29), which were in line with the estimate of ($0.29).
Revenue of $7,053,000 declined by 6.33% year over year, which missed the estimate of $7,100,000.
Guidance
TransMedics Group hasn't issued any earnings guidance for the time being.
TransMedics Group hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 04, 2021
Time: 04:30 PM
Price Action
Company's 52-week high was at $49.50
52-week low: $11.51
Price action over last quarter: down 25.07%
Company Profile
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes the technology to replicate near-physiologic conditions for donor organs outside of the human body.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.